Other Events ·
On September 8, 2026, Pharvaris N.V. announced positive topline data from the CHAPTER-3 pivotal study of deucrictibant…
PHVSPharvaris N.V.
On September 8, 2026, Pharvaris N.V. announced positive topline data from the CHAPTER-3 pivotal study of deucrictibant XR for the prophylaxis of hereditary angioedema (HAE) attacks. This clinical milestone provides critical evidence supporting the regulatory approval pathway for its lead asset in preventing HAE episodes. The company operates in the biopharmaceutical industry, focusing on the development and commercialization of treatments for rare diseases.